Last reviewed · How we verify
GSH
GSH (glutathione) is an antioxidant tripeptide that replenishes cellular glutathione levels to reduce oxidative stress and support cellular defense mechanisms.
GSH (glutathione) is an antioxidant tripeptide that replenishes cellular glutathione levels to reduce oxidative stress and support cellular defense mechanisms. Used for Age-related oxidative stress and cellular dysfunction (investigational).
At a glance
| Generic name | GSH |
|---|---|
| Also known as | Glutathione |
| Sponsor | AgelessRx |
| Drug class | Antioxidant / Nutritional supplement |
| Target | Glutathione synthesis and oxidative stress pathways |
| Modality | Small molecule |
| Therapeutic area | Aging / Longevity / General wellness |
| Phase | Phase 3 |
Mechanism of action
Glutathione is a naturally occurring antioxidant composed of three amino acids (glutamate, cysteine, and glycine) that plays a critical role in protecting cells from oxidative damage and supporting detoxification pathways. By supplementing or enhancing glutathione levels, GSH aims to mitigate age-related oxidative stress and support cellular health. This mechanism is theorized to have broad anti-aging and cytoprotective effects across multiple organ systems.
Approved indications
- Age-related oxidative stress and cellular dysfunction (investigational)
Common side effects
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. (PHASE1)
- Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. (PHASE2, PHASE3)
- Glutathione in Mild Cognitive Impairment (EARLY_PHASE1)
- Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (PHASE2)
- Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis (PHASE2)
- Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |